Quick Answer
Intellia Therapeutics, Inc. reported Stockholders Equity of $671.39 million for the year ending 2025.
- Intellia Therapeutics, Inc. showed a decrease of -23.0% in Stockholders Equity from 2024 to 2025.
- This data is from Intellia Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on February 26, 2026.
- XBRL data for this metric is available from 2014 to 2025 (13 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2016: -$27.14 million | Q2 2016: $223.60 million | Q3 2016: $218.12 million | Q1 2017: $199.88 million | Q2 2017: $187.59 million | Q3 2017: $175.85 million | Q1 2018: $295.50 million | Q2 2018: $279.34 million | Q3 2018: $263.27 million | Q1 2019: $264.34 million | Q2 2019: $276.87 million | Q3 2019: $275.65 million | Q1 2020: $247.76 million | Q2 2020: $351.59 million | Q3 2020: $329.62 million | Q1 2021: $545.87 million | Q2 2021: $494.81 million | Q3 2021: $1.11 billion | Q1 2022: $953.75 million | Q2 2022: $880.55 million | Q3 2022: $824.95 million | Q1 2023: $1.19 billion | Q2 2023: $1.10 billion | Q3 2023: $1.04 billion | Q1 2024: $1.04 billion | Q2 2024: $971.06 million | Q3 2024: $962.62 million | Q1 2025: $779.92 million | Q2 2025: $715.26 million | Q3 2025: $748.42 million.
- Historical annual values: Fiscal year 2025: $671.39 million | Fiscal year 2024: $871.96 million | Fiscal year 2023: $1.05 billion | Fiscal year 2022: $1.24 billion | Fiscal year 2021: $1.04 billion | Fiscal year 2020: $527.07 million | Fiscal year 2019: $269.88 million | Fiscal year 2018: $277.92 million | Fiscal year 2017: $300.60 million | Fiscal year 2016: $209.84 million | Fiscal year 2015: -$21.20 million | Fiscal year 2014: $7.57 million | Fiscal year 2014: $0.00.
- Data sourced from SEC EDGAR public filings as of August 5, 2026.
Last verified: